Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
63.35%
Operating Margin
36.10%
Net Margin
22.15%
Efficiency Metrics
Revenue per Expense Ratio
1.49
R&D as % of Revenue
2.02%
Earnings Quality
EBITDA Margin
38.02%
Income Tax Rate
22.05%
EPS
5.0200000000
Balance Sheet Analysis
Current Ratio
0.75
Cash Ratio
0.12
Working Capital
$-6.63B
Debt to Equity
47,909,000,000.0
Debt to Assets
73.36%
Equity Ratio
-17.19%
Cash Flow Analysis
Operating Cash Flow Ratio
26.17%
Free Cash Flow Ratio
22.41%
CapEx to Revenue
3.76%
Dividends Paid
$7.96B
Stock Buybacks
No buybacks
Total Shareholder Returns
$7.96B
Cash Position Change
-2.21%
Key Takeaways (2023 FY)
Increased dividend payments by 1.81%
Increased R&D investment by 10.44%
Detailed Growth Metrics
Core Performance
Revenue
10.74%
Net Income
-13.89%
EPS
-13.75%
Operating Income
1.22%
Operational Efficiency
R&D Expenses
10.44%
SG&A Expenses
26.47%
Operating Cash Flow
-14.80%
Free Cash Flow
-18.95%
Balance Sheet Health
Assets
5.87%
Debt
11.10%
Book Value per Share
-49.48%
Inventory
8.98%
Shareholder Returns
Dividends per Share
1.81%
Shares Outstanding
0.13%
Long Term Trends
3Y Revenue/Share
22.98%
5Y Revenue/Share
18.96%
3Y Dividend/Share
8.50%
5Y Dividend/Share
15.90%